Price
No data yet.
Social Signal Score
Analyst Ratings
4 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Jean-Pierre Sommadossi
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 55
- Beta
- 0.28
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 3.73
Financials
Revenue
$0.00-100.0%Net Income
$-32.93MEBITDA
$-32.70MFree Cash Flow
$-37.08MEPS (diluted)
$-0.41Shares Outstanding (diluted)
80.05M+693.3%Operating Expenses
$35.10MCash & Debt
$219.47MReturn of Capital
$746.0KQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-158.35M | $-1.94 |
| 2024 | $0.00 | $-168.38M | $-2.00 |
| 2023 | $0.00 | $-135.96M | $-1.63 |
| 2022 | $0.00 | $-115.91M | $-1.39 |
| 2021 | $351.37M | $121.19M | $1.46 |
| 2020 | $48.63M | $-10.95M | $-0.13 |
| 2019 | $0.00 | $-13.46M | $-0.16 |
| 2018 | $0.00 | $-9.06M | $-0.90 |
Valuation
AVIRhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
125Social Signal Score
Mentions (2)
- Newsseekingalpha.com·54d ago·Positive
Atea Pharmaceuticals, Inc. (AVIR) Q2 2026 Earnings Call Transcript Atea Pharmaceuticals, Inc. (AVIR) Q2 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·54d ago·Positive
Atea Pharmaceuticals Q2 Earnings Call Highlights Atea Pharmaceuticals NASDAQ: AVIR reported positive top-line results from its Phase III C-BEYOND trial of bemnifosbuvir/ruzasvir for chronic hepatitis C virus, saying the study met its primary and secondary endpoints against the standard-of-care regimen sofosbuvir/velpatasvir, marketed as Epclusa.
View source ↗
Earnings
Wed, Nov 11(in 5 weeks)
Consensus estimate $-0.51 per share
Typical surprise +4.3% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 12$-0.41 vs $-0.56beat
- Tue, May 12$-0.57 vs $-0.60beat
- Thu, Mar 5$-0.57 vs $-0.49miss
- Wed, Nov 12$-0.53 vs $-0.46miss
- Thu, Aug 7$-0.44 vs $-0.46beat
- Mon, May 12$-0.40 vs $-0.56beat
Estimates and results for AVIR via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by AVIR officers and directors.
- Bought
- $51k
- Sold
- —
2 trades
0 trades
- Murphy Polly A.bought
- Murphy Polly A.bought
98 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in AVIR.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.